For example, 68Ga-PSMA PET/CT guided 177Lu-PSMA therapy has been considered as a promising direction for precise diagnosis and treatment of refractory prostate cancer (Maurer et al., 2016; Giovacchini et al., 2017). This evidence concerns the gene FOLH1 and prostate carcinoma.